Indium (111In) capromab pendetide - WikiMD's WELLNESSPEDIA

Indium (¹¹¹In) capromab pendetide

INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	151763-64-3
PubChem
DrugBank
ChemSpider	none
KEGG

Indium (¹¹¹In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.^[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.^[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).^[1]

Early trials with yttrium (⁹⁰Y) capromab pendetide were also conducted.^[3]

References[edit]

↑ ^1.0 ^1.1 "Indium-111 capromab pendetide in the management of recurrent prostate cancer".Expert Review of Anticancer Therapy.2008;8(2)
175–81.doi:10.1586/14737140.8.2.175.PMID:18279057.
↑ WHO Drug Information
↑ Kahn, Daniel."A Phase II Study of [⁹⁰Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy".Cancer Biotherapy & Radiopharmaceuticals.1999;14(2)
99.doi:10.1089/cbr.1999.14.99.

Diagnostic radiopharmaceuticals (V09)

Central nervous system	* ^99mTc (Exametazime, Pentetic acid) ¹²³I (Ioflupane (123I) Iofetamine (123I) Iolopride (123I) Iomazenil) ¹⁸F (Florbetapir (18F), Flutemetamol (18F))
Skeletal system	* ^99mTc (Medronic acid)
Renal	* ¹²³I (Sodium iodohippurate) ⁶⁴Cu ETS2 ^99mTc (Mertiatide, Pentetic acid)
Gastrointestinal/Hepatic	* ⁷⁵Se (SeHCAT)
Respiratory system	* ¹³³Xe ^81mKr ^99mTc (^99mTc-MAA, Pentetic acid)

Isotopes used:

Monoclonal antibodies for tumors

Tumor

Human	* Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	* Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	* Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	* Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	* Catumaxomab Ertumaxomab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Stub icon

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page.

This medical article is a stub. You can help WikiMD by expanding the page.